It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Acute exposure to high-dose gamma radiation due to radiological disasters or cancer radiotherapy can result in radiation-induced lung injury (RILI), characterized by acute pneumonitis and subsequent lung fibrosis. A microfluidic organ-on-a-chip lined by human lung alveolar epithelium interfaced with pulmonary endothelium (Lung Alveolus Chip) is used to model acute RILI in vitro. Both lung epithelium and endothelium exhibit DNA damage, cellular hypertrophy, upregulation of inflammatory cytokines, and loss of barrier function within 6 h of radiation exposure, although greater damage is observed in the endothelium. The radiation dose sensitivity observed on-chip is more like the human lung than animal preclinical models. The Alveolus Chip is also used to evaluate the potential ability of two drugs - lovastatin and prednisolone - to suppress the effects of acute RILI. These data demonstrate that the Lung Alveolus Chip provides a human relevant alternative for studying the molecular basis of acute RILI and may be useful for evaluation of new radiation countermeasure therapeutics.
Acute exposure to radiation can lead to acute pneumonitis, fibrosis or death. Here the authors develop an alveolus-on chip model to study the molecular characteristics of radiation induced lung injury, better understand radiation induced lung disease and facilitate drug screening.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Boston Children’s Hospital and Harvard Medical School, Vascular Biology Program and Department of Surgery, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, USA (GRID:grid.38142.3c)
2 Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, USA (GRID:grid.38142.3c)
3 Boston Children’s Hospital and Harvard Medical School, Vascular Biology Program and Department of Surgery, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
4 Boston Children’s Hospital and Harvard Medical School, Vascular Biology Program and Department of Surgery, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, USA (GRID:grid.38142.3c); Harvard University, Harvard John A. Paulson School of Engineering and Applied Sciences, Cambridge, USA (GRID:grid.38142.3c) (ISNI:0000 0004 1936 754X)